

Nikolaj KunÅ,e

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9350439/publications.pdf>

Version: 2024-02-01

32
papers

836
citations

623734

14
h-index

477307

29
g-index

45
all docs

45
docs citations

45
times ranked

836
citing authors

#	ARTICLE	IF	CITATIONS
1	The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and Relapse. <i>European Addiction Research</i> , 2022, 28, 56-67.	2.4	3
2	Protocol for the Lovisenberg Open Acute Door Study (LOADS): a pragmatic randomised controlled trial to compare safety and coercion between open-door policy and usual-care services in acute psychiatric inpatients. <i>BMJ Open</i> , 2022, 12, e058501.	1.9	1
3	Adapting treatment length to opioid-dependent individuals'™ needs and preferences: a 2-year follow-up to a 1-year study of extended-release naltrexone. <i>Addiction</i> , 2021, 116, 2084.	3.3	5
4	Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical Trial. <i>American Journal on Addictions</i> , 2021, 30, 453-460.	1.4	2
5	Commentary on Nunes et al . (2020): Blocked opioid use in antagonist treatment"™time for cognitive and user-centered perspectives. <i>Addiction</i> , 2020, 115, 247-248.	3.3	1
6	T212. No Increase in Chronic Pain Among Opioid-Dependent Individuals Randomized to Treatment With Extended-Release Naltrexone Compared to Buprenorphine-Naloxone. <i>Biological Psychiatry</i> , 2019, 85, S211-S212.	1.3	1
7	Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial. <i>European Addiction Research</i> , 2019, 25, 303-309.	2.4	7
8	Extended-release opioid antagonists and HIV treatment. <i>Lancet HIV</i> , 2019, 6, e206-e207.	4.7	0
9	Intact responses to non-drug rewards in long-term opioid maintenance treatment. <i>Neuropsychopharmacology</i> , 2019, 44, 1456-1463.	5.4	10
10	Opioid addiction: long-acting formulations for a long-term disorder. <i>Lancet</i> , 2019, 393, 723-724.	13.7	0
11	Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone. <i>JAMA Psychiatry</i> , 2019, 76, 127.	11.0	44
12	No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study. <i>American Journal on Addictions</i> , 2019, 28, 77-85.	1.4	16
13	Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial. <i>Addiction</i> , 2018, 113, 1840-1849.	3.3	20
14	Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence. <i>JAMA Psychiatry</i> , 2017, 74, 1197.	11.0	200
15	Interest in Extended Release Naltrexone among Opioid Users. <i>European Addiction Research</i> , 2016, 22, 301-305.	2.4	5
16	Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX). <i>BMC Pharmacology & Toxicology</i> , 2016, 17, 18.	2.4	18
17	The Norwegian Offender Mental Health and Addiction Study "™ Design and Implementation of a National Survey and Prospective Cohort Study. <i>Substance Abuse: Research and Treatment</i> , 2015, 9s2, SART.S23546.	0.9	12
18	Injectable and implantable sustained release naltrexone in the treatment of opioid addiction. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 264-271.	2.4	51

#	ARTICLE	IF	CITATIONS
19	Naltrexone Depot Formulations for Opioid and Alcohol Dependence: A Systematic Review. CNS Neuroscience and Therapeutics, 2011, 17, 629-636.	3.9	57
20	Patients receiving opiate substitution have elevated mortality risks at the start and end of treatment. Evidence-Based Mental Health, 2011, 14, 39-39.	4.5	0
21	Patients receiving opiate substitution have elevated mortality risks at the start and end of treatment. Evidence-Based Mental Health, 2011, 14, 39-39.	4.5	0
22	Challenges to antagonist blockade during sustained-release naltrexone treatment. Addiction, 2010, 105, 1633-1639.	3.3	21
23	Naltrexone Implants Compared to Methadone: Outcomes Six Months after Prison Release. European Addiction Research, 2010, 16, 139-145.	2.4	74
24	Retention in naltrexone implant treatment for opioid dependence. Drug and Alcohol Dependence, 2010, 111, 166-169.	3.2	21
25	Treatment research in prison: Problems and solutions in a randomized trial. Addiction Research and Theory, 2010, 18, 1-13.	1.9	20
26	Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. British Journal of Psychiatry, 2009, 194, 541-546.	2.8	83
27	Sustained release Naltrexone, a promising alternative in treatment of opiate addiction. Canadian Journal of Addiction, 2009, 1, 42.	0.4	0
28	Sustained-Release Naltrexone For Opioid Dependence. The Cochrane Library, 2008, , CD006140.	2.8	67
29	Drug Screening of Hair by Liquid Chromatography-Tandem Mass Spectrometry. Journal of Analytical Toxicology, 2008, 32, 364-372.	2.8	83
30	Opioid overdose deaths can occur in patients with naltrexone implants. Medical Journal of Australia, 2007, 187, 56-56.	1.7	3
31	BLAME THE COUNSELLING, NOT THE IMPLANT. A RESPONSE TO OLIVER, HORSPOOL & KEEN (2005). Addiction, 2005, 100, 1027-1028.	3.3	1
32	Treatment research in prison: Problems and solutions in a randomized trial. Addiction Research and Theory, 0, , 1-13.	1.9	1